Taysha Gene Therapies (TSHA) announced results from a new supplemental data analysis from Part A of the REVEAL Phase 1/2 adult/adolescent and pediatric trials evaluating TSHA-102 in females with Rett syndrome at the 54th Child Neurology Society Annual Meeting. The analysis provides supportive evidence of additional functional gains in skills and improvements across core disease characteristics that are outside of the natural history defined developmental milestones, further highlighting the consistent, multi-domain impact of TSHA-102 on activities of daily living. New supplemental analysis of efficacy scales provides supportive evidence of additional functional gains, with 100% of patients demonstrating multiple skill gains/improvements outside the natural history defined developmental milestones
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Taysha Gene Therapies price target raised to $12 from $7 at Baird
- Neurogene looks ‘deeply undervalued’ after Taysha news, says H.C. Wainwright
- Berkshire to acquire OxyChem, OpenAI reaches $500B valuation: Morning Buzz
- Promising Prospects for Taysha Gene Therapies: Buy Rating Backed by Strategic Advancements and Regulatory Endorsements
- Needham ups Taysha target on ‘derisking’ TSHA-102 news